Stockscreener 앱 받기
8.32
1.09%
0.09
시간 외 거래:
8.32
전일 마감가:
$8.23
열려 있는:
$8.22
하루 거래량:
933.97K
Relative Volume:
0.70
시가총액:
$818.62M
수익:
$14.79M
순이익/손실:
$-174.33M
주가수익비율:
-4.1149
EPS:
-2.0219
순현금흐름:
$-157.44M
1주 성능:
+3.74%
1개월 성능:
+13.82%
6개월 성능:
+31.65%
1년 성능:
+208.15%
1일 변동 폭
$8.00
$8.36
1주일 범위
$7.61
$8.8661
52주 변동 폭
$2.41
$8.8661
솔리드 바이오 Stock (SLDB) Company Profile
명칭
Solid Biosciences Inc
전화
617-337-4680
주소
500 RUTHERFORD AVENUE, CHARLESTOWN, MA
Compare SLDB vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SLDB
Solid Biosciences Inc
|
8.32 | 809.76M | 14.79M | -174.33M | -157.44M | -2.0219 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
솔리드 바이오 Stock (SLDB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-20 | 개시 | Guggenheim | Buy |
| 2025-12-04 | 개시 | Needham | Buy |
| 2025-06-26 | 개시 | Citigroup | Buy |
| 2025-01-08 | 개시 | Truist | Buy |
| 2024-12-13 | 개시 | Wedbush | Outperform |
| 2024-12-10 | 개시 | JMP Securities | Mkt Outperform |
| 2024-07-15 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-06-24 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-05-31 | 재개 | Piper Sandler | Overweight |
| 2024-03-28 | 개시 | William Blair | Outperform |
| 2024-03-15 | 개시 | Citigroup | Buy |
| 2024-03-14 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-12-08 | 개시 | H.C. Wainwright | Buy |
| 2021-07-12 | 개시 | Piper Sandler | Neutral |
| 2021-05-27 | 개시 | Jefferies | Buy |
| 2021-03-16 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-09 | 개시 | Barclays | Overweight |
| 2021-01-08 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2020-07-28 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-05-07 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-10-11 | 개시 | Evercore ISI | Outperform |
| 2019-08-29 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2019-08-19 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-08-16 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2019-05-14 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2019-05-14 | 다운그레이드 | Goldman | Neutral → Sell |
| 2019-02-08 | 업그레이드 | Citigroup | Sell → Neutral |
| 2019-02-08 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2018-11-06 | 개시 | Citigroup | Sell |
| 2018-09-06 | 개시 | Credit Suisse | Neutral |
모두보기
솔리드 바이오 주식(SLDB)의 최신 뉴스
Needham Maintains Solid Biosciences(SLDB.US) With Buy Rating, Maintains Target Price $19 - Moomoo
Dow Update: Is Solid Biosciences Inc part of any ETF2026 Pullbacks & Low Risk Entry Point Guides - baoquankhu1.vn
Sell Signal: Can Solid Biosciences Inc maintain its current growth rate2026 Short Interest & Fast Moving Trade Plans - baoquankhu1.vn
Solid Biosciences Inc. Files Form 8-K with SEC Detailing Company Information and No Amendments as of April 10, 2026 - Minichart
Solid Biosciences reclassifies board member Ilan Ganot to Class I director By Investing.com - Investing.com Australia
Solid Biosciences reclassifies board member Ilan Ganot to Class I director - Investing.com
Solid Biosciences Adjusts Board Classes in Governance Move - TipRanks
Solid Biosciences (NASDAQ: SLDB) asks shareholders to double authorized shares to 480,000,000 - Stock Titan
Board reshuffle at Solid Biosciences (NASDAQ: SLDB) balances director classes - Stock Titan
Activity Recap: Can Solid Biosciences Inc maintain its current growth rateOil Prices & Long-Term Safe Return Strategies - baoquankhu1.vn
Aug Gainers: What are Solid Biosciences Incs earnings expectationsWeekly Trade Analysis & Capital Efficient Trade Techniques - baoquankhu1.vn
Solid Biosciences to Participate at Upcoming Investor Conferences - marketscreener.com
Solid Biosciences CEO speaks April 14; investor meetings follow - Stock Titan
Solid Biosciences (NASDAQ:SLDB) Trading 6.4% HigherHere's What Happened - MarketBeat
SLDB PE Ratio & Valuation, Is SLDB Overvalued - Intellectia AI
Solid Biosciences Stock: Gene Therapy Pipeline and Strategic Position in Neuromuscular Disorders - AD HOC NEWS
Director at Solid Biosciences (NASDAQ: SLDB) exercises RSUs - Stock Titan
[EFFECT] Solid Biosciences Inc. SEC Filing - Stock Titan
Big Picture: Whats the beta of Solid Biosciences Inc stockMarket Growth Review & Real-Time Buy Signal Notifications - baoquankhu1.vn
Solid Biosciences (NASDAQ:SLDB) Trading Down 6.7%Here's Why - MarketBeat
Solid Bio wins new buy at Guggenheim on lead asset - MSN
Aug Analyst Calls: Is Solid Biosciences Inc part of any ETF2026 Highlights & High Accuracy Investment Signals - baoquankhu1.vn
Solid Biosciences (NASDAQ:SLDB) Shares Up 5.5% After Analyst Upgrade - MarketBeat
Truist Financial Upgrades Solid Biosciences (NASDAQ:SLDB) to "Strong-Buy" - MarketBeat
JPMorgan Chase & Co. Raises Solid Biosciences (NASDAQ:SLDB) Price Target to $12.00 - MarketBeat
SLDB: JP Morgan Raises Price Target to $12 with Overweight Ratin - GuruFocus
HC Wainwright Expects Higher Earnings for Solid Biosciences - MarketBeat
Solid Biosciences (NASDAQ:SLDB) Earns "Buy" Rating from HC Wainwright - MarketBeat
H.C. Wainwright Maintains Solid Biosciences(SLDB.US) With Buy Rating, Maintains Target Price $20 - Moomoo
SLDB: HC Wainwright & Co. Reiterates Buy Rating with $20 Target - GuruFocus
Solid Biosciences Inc. (NASDAQ:SLDB) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Solid Biosciences Faces Pricing Challenges Amid Changing Gene Therapy Economics Due to Updated Regulations - Bitget
Guggenheim initiates coverage of Solid Biosciences (SLDB) with buy recommendation - MSN
Evolving Tax Rules and New Excise Levies Threaten Solid Biosciences’ Profitability and Cash Flows - TipRanks
RA CAPITAL MANAGEMENT, L.P. Reduces Stake in Solid Biosciences Inc - GuruFocus
Guggenheim Initiates Coverage on Solid Biosciences (SLDB) with B - GuruFocus
Will Solid Biosciences Inc stock recover after earnings2026 Key Lessons & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
Solid Biosciences (NASDAQ:SLDB) Shares Gap UpWhat's Next? - MarketBeat
Solid Bio stock wins new Buy at Guggenheim (SLDB:NASDAQ) - Seeking Alpha
SLDB: Guggenheim Initiates Coverage with a 'Buy' Rating at $26 | - GuruFocus
Guggenheim Initiates Coverage on Solid Biosciences (NASDAQ:SLDB) - MarketBeat
Solid Biosciences (NASDAQ:SLDB) Earns "Buy" Rating from Chardan Capital - MarketBeat
Solid Biosciences (SLDB) Receives Maintained 'Buy' Rating from C - GuruFocus
Solid Biosciences (NASDAQ:SLDB) Given "Buy" Rating at Needham & Company LLC - MarketBeat
Solid Biosciences (SLDB) Receives Buy Rating and Positive Outloo - GuruFocus
Guggenheim Initiates Solid Biosciences at Buy With $26 Price Target - marketscreener.com
SLDB: Needham Reiterates 'Buy' Rating with Price Target of $19.0 - GuruFocus
Solid Biosciences Inc. 2025 Annual Report: Advancing Gene Therapy for Neuromuscular and Cardiac Diseases - Minichart
Solid Biosciences (NASDAQ:SLDB) Posts Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat
Solid Biosciences (SLDB) Strengthens Financial Position with Inc - GuruFocus
Solid Biosciences (NASDAQ: SLDB) resale registration for 42.8M shares - Stock Titan
솔리드 바이오 (SLDB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):